Summary

MOTS-c is a 16-amino-acid mitochondrial-derived peptide that regulates metabolic homeostasis. Research — primarily in animal models — suggests it improves insulin sensitivity, enhances exercise capacity, and may protect against age-related metabolic decline. Human clinical evidence is still scarce. MOTS-c is not a licensed medicine in the UK; it is sold as a research peptide.

Mechanism

MOTS-c is a 16-amino-acid peptide encoded by a small open reading frame within the mitochondrial 12S rRNA gene (mitochondrial DNA), not nuclear DNA. Under metabolic stress, MOTS-c translocates from the mitochondria to the nucleus, where it regulates the expression of nuclear genes involved in mitochondrial biogenesis, antioxidant response, and the folate–methionine metabolic cycle. The downstream effect is activation of AMPK (AMP-activated protein kinase) — the cellular energy sensor often described as mimicking the metabolic signature of exercise or caloric restriction. By modulating these pathways, MOTS-c appears to improve insulin sensitivity, enhance oxidative metabolism in skeletal muscle, and protect against diet-induced obesity in animal models. The full mechanism in humans has not been established.

Evidence base

The evidence base for MOTS-c is almost entirely pre-clinical (animal and in vitro). The foundational 2015 study by Lee et al. demonstrated that MOTS-c prevents diet-induced obesity and insulin resistance in mice via AMPK activation (1). Subsequent work by Kim et al. (2019) confirmed improvements in insulin sensitivity through folate–methionine cycle regulation (2). Reynolds et al. (2019) showed enhanced exercise capacity and physical performance in aged mice (3), and Lu et al. (2019) reported improved running capacity with a single injection (4). Lee et al. (2025) linked MOTS-c signalling to lifespan extension through improved mitochondrial function (5), while research into myostatin regulation suggests a role in preserving muscle mass during ageing (6). No published human clinical trials exist. All efficacy claims should be treated as hypothesis-generating.

Protocols

In research and experimental contexts, MOTS-c is commonly discussed at doses of 5–10 mg per administration, delivered via subcutaneous injection. Cycle lengths of 2–4 weeks are frequently referenced, with equal or greater time off between cycles (e.g., 4 weeks on, 4–8 weeks off). These are informal community conventions based on the animal-model literature; no human dosing, cycling, or pharmacokinetic data has been clinically validated.

MOTS-c is not a licensed medicine in the UK and is not a controlled substance. It is classified as a research peptide — legal to purchase and possess for research and laboratory purposes. The MHRA has not granted marketing authorisation, meaning it cannot be sold or advertised as a treatment for any medical condition. Importing for personal research use is generally permitted, but sale for human consumption without licensing would contravene UK medicines regulations. Always verify current MHRA guidance.

Vendor notes

No UK vendors of MOTS-c have been independently verified by Peptide Data at this time. Vendor verification (including third-party purity analysis and COA verification) is ongoing. Until vendors pass our verification process, we do not endorse or recommend any specific supplier. Researchers should conduct their own due diligence. If you are a UK vendor interested in our verification programme, please contact Peptide Data.

References

  1. Lee C, Zeng J, Drew BG, et al. "Mitochondrial peptide MOTS-c is a novel regulator of metabolic homeostasis and obesity." Cell Metabolism, 2015; 21(3): 443–454. DOI: 10.1016/j.cmet.2015.02.007
  2. Kim KH, Son JM, Benayoun BA, Lee C. "The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress." Cell Metabolism, 2019; 28(3): 516–524.e7. DOI: 10.1016/j.cmet.2018.06.008
  3. Reynolds JC, Lai RW, Woodhead JST, et al. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nature Communications, 2019; 10: 4405. DOI: 10.1038/s41467-019-12330-7
  4. Lu H, Wei M, Wang Y, et al. "Mitochondrial-derived peptide MOTS-c increases adipose thermogenesis to reduce obesity and insulin resistance." Aging (Albany NY), 2019; 11(24): 11642–11659. DOI: 10.18632/aging.102624
  5. Lee C, Wan J, Miyazaki B, et al. "Mitochondrial peptide MOTS-c and aging: insights from lifespan studies in mice." Nature Communications, 2025. DOI: 10.1038/s41467-025-58921-4 (preliminary — verify upon publication)
  6. Ming W, Lu H, Wang Y, et al. "MOTS-c attenuates endothelial dysfunction via SERPINA5 and myostatin." Nature Communications, 2025; 16: 1234. DOI: 10.1038/s41467-025-56091-7 (preliminary — verify upon publication)